Concepedia

Yunhang Guo

YG

Statistics

Publications

10

Citations

633

H-Index

10

Active since

2008

Affiliations

BeiGene (China)(Current)

Dalian University of Technology

Beijing University of Technology

Yunhang Guo is an author at BeiGene (China) specializing in hematologic malignancy therapy, cancer pharmacology, and pharmacology.

ORCID

Publications per year

2008–2024

10

Publications

10

Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase

Yunhang Guo, Ye Liu, Nan Hu et al. · Journal of Medicinal Chemistry · 2019 · 349 citations · Full text

, , +16

Sonrotoclax overcomes BCL2 G101V mutation–induced venetoclax resistance in preclinical models of hematologic malignancy

Jiuyang Liu, Shuran Li, Qin Wang et al. · Blood · 2024 · 71 citations · Full text

, , +15

Abstract 2597: BGB-3111 is a novel and highly selective Bruton's tyrosine kinase (BTK) inhibitor

Na Li, Zhijian Sun, Ye Liu et al. · Cancer Research · 2015 · 47 citations

, , +17

Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2

Yunhang Guo, Yunhang Guo, Hai Xue et al. · Journal of Medicinal Chemistry · 2024 · 42 citations · Full text

, , +14

Preparation and biological evaluation of 99mTc-CO-MIBI as myocardial perfusion imaging agent

Xiangji Chen, Yunhang Guo, Qiuyan Zhang et al. · Journal of Organometallic Chemistry · 2008 · 24 citations

, , +14

1–5 of 10